Skip Nav Destination
Issues
1 September 2021
-
Cover Image
Cover Image
SENTI-101 is a novel allogeneic cell therapy for the treatment of peritoneal carcinomatosis, including advanced ovarian cancer. Genetically modified mesenchymal stem cells deliver IL-12 and IL-21 to peritoneal tumors, attracting and activating immune cells. Read the full article on page 1508.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
MCT First Disclosures
SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors
Alba Gonzalez-Junca; Frances D. Liu; Archana S. Nagaraja; Alyssa Mullenix; Chen-Ting Lee; Russell M. Gordley; Daniel O. Frimannsson; Ori Maller; Brian S. Garrison; Dharini Iyer; Anissa Benabbas; Tiffany A. Truong; Allison Quach; Mengxi Tian; Rowena Martinez; Rishi Savur; Alyssa Perry-McNamara; Denny Nguyen; Niran Almudhfar; Carmina Blanco; Christina Huynh; Asish Nand; Yu-An E. Lay; Ashita Magal; Sravani Mangalampalli; Philip J. Lee; Timothy K. Lu; Gary Lee
Reviews
Small Molecule Therapeutics
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma
Matthias A. Karajannis; Audrey Mauguen; Ekrem Maloku; Qingwen Xu; Erin M. Dunbar; Scott R. Plotkin; Anna Yaffee; Shiyang Wang; J. Thomas Roland; Chandranath Sen; Dimitris G. Placantonakis; John G. Golfinos; Jeffrey C. Allen; Nicholas A. Vitanza; Luis A. Chiriboga; Robert J. Schneider; Jingjing Deng; Thomas A. Neubert; Judith D. Goldberg; David Zagzag; Filippo G. Giancotti; Jaishri O. Blakeley
β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model
Minjing Zou; Huda A. BinEssa; Yousif H. Al-Malki; Suhad Al-Yahya; Monther Al-Alwan; Ibrahim Al-Jammaz; Khalid S.A. Khabar; Falah Almohanna; Abdullah M. Assiri; Brian F. Meyer; Ali S. Alzahrani; Futwan A. Al-Mohanna; Yufei Shi
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
Sonja J. Gill; Paul W.G. Wijnhoven; Jacqueline H.L. Fok; Rebecca L. Lloyd; Jonathan Cairns; Joshua Armenia; Jenni Nikkilä; Alan Lau; Christopher J. Bakkenist; Susan M. Galbraith; Conchita Vens; Mark J. O'Connor
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
Nyree Crawford; Katie J. Stott; Tamas Sessler; Christopher McCann; William McDaid; Andrea Lees; Cheryl Latimer; Jennifer P. Fox; Joanne M. Munck; Tomoko Smyth; Alpesh Shah; Vanessa Martins; Mark Lawler; Philip D. Dunne; Emma M. Kerr; Simon S. McDade; Vicky M. Coyle; Daniel B. Longley
SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Hirohisa Kano; Eiki Ichihara; Hiromi Watanabe; Kazuya Nishii; Chihiro Ando; Takamasa Nakasuka; Kiichiro Ninomiya; Yuka Kato; Toshio Kubo; Kammei Rai; Kadoaki Ohashi; Katsuyuki Hotta; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
Cheng Wu; Shan Peng; Patrick G. Pilié; Chuandong Geng; Sanghee Park; Ganiraju C. Manyam; Yungang Lu; Guang Yang; Zhe Tang; Shakuntala Kondraganti; Daoqi Wang; Courtney W. Hudgens; Debora A. Ledesma; Mario L. Marques-Piubelli; Carlos A. Torres-Cabala; Jonathan L. Curry; Patricia Troncoso; Paul G. Corn; Bradley M. Broom; Timothy C. Thompson
Large Molecule Therapeutics
Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
Wen-Hsin Sandy Lee; Zhiyong Ye; Alice M.S. Cheung; Y.P. Sharon Goh; Hsueh Ling Janice Oh; Ravisankar Rajarethinam; Siok Ping Yeo; Mun Kuen Soh; Esther Hian Li Chan; Lip Kun Tan; Soo-Yong Tan; Charles Chuah; Wee Joo Chng; John E. Connolly; Cheng-I Wang
Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
Keiichiro Yokota; Satoshi Serada; Shigehiro Tsujii; Keisuke Toya; Tsuyoshi Takahashi; Takashi Matsunaga; Minoru Fujimoto; Sunao Uemura; Tsutomu Namikawa; Ichiro Murakami; Shogo Kobayashi; Hidetoshi Eguchi; Yuichiro Doki; Kazuhiro Hanazaki; Tetsuji Naka
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
James Harper; Shannon Burke; Jon Travers; Nicola Rath; Andrew Leinster; Christel Navarro; Ruth Franks; Rebecca Leyland; Kathy Mulgrew; Kelly McGlinchey; Lee Brown; Simon J. Dovedi; Jens-Oliver Koopmann; Nicholas M. Durham; Xing Cheng; Hong Jin; Jim Eyles; Robert W. Wilkinson; Danielle Carroll
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
Hong Zheng; Yunong Gao; Hongyan Guo; Li Li; Qingshui Li; Heng Cui; An Lin; Lixin Sun; Yuanjing Hu; Shan Kang; Wei Duan; Lingya Pan; Shuzhen Wang; Yingjie Yang; Yunxia Li; Weimin Kong; Yang Xiang; Xiaofei Tian; Bin Ling; Chunfang Ha; Wenpei Bai
Models and Technologies
Advertisement